公开(公告)号：WO2009067578A3

公开(公告)日：2009-11-26

申请号：PCT/US2008084142

申请日：2008-11-20

Applicant: ABBOTT LAB ,  VON GELDERN THOMAS W ,  BURKALOW JUFANG H ,  BARNES DAVID M ,  HAIGHT ANGHONY R ,  HENGEVELD JOHN E ,  LI XIAOFENG ,  MCLAUGHLIN MAUREEN A ,  NOONAN WILLIAM T ,  PEI ZHONGHUA ,  WU-WONG JINSHYUN RUTH

Inventor： VON GELDERN THOMAS W ,  BURKALOW JUFANG H ,  BARNES DAVID M ,  HAIGHT ANGHONY R ,  HENGEVELD JOHN E ,  LI XIAOFENG ,  MCLAUGHLIN MAUREEN A ,  NOONAN WILLIAM T ,  PEI ZHONGHUA ,  WU-WONG JINSHYUN RUTH

IPC: C07C401/00

CPC classification number: C07C401/00 ,  C07C2601/14 ,  C07C2602/24

Abstract: The invention relates to compounds that are vitamin D receptor activators, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

Abstract translation: 本发明涉及作为维生素D受体激活剂的化合物，包含此类化合物的组合物，使用此类化合物和组合物的方法，制备此类化合物的方法以及在此类过程中获得的中间体。

公开(公告)号：WO2007027651A2

公开(公告)日：2007-03-08

申请号：PCT/US2006033620

申请日：2006-08-25

Applicant: ABBOTT LAB ,  PEI ZHONGHUA ,  VON GELDERN THOMAS ,  MADAR DAVID J ,  LI XIAOFENG ,  BASHA FATIMA ,  YONG HONG ,  LONGENECKER KENTON L ,  BACKES BRADLEY J ,  JUDD ANDREW S ,  MULHERN MATHEW M ,  STEWART KENT D

Inventor： PEI ZHONGHUA ,  VON GELDERN THOMAS ,  MADAR DAVID J ,  LI XIAOFENG ,  BASHA FATIMA ,  YONG HONG ,  LONGENECKER KENTON L ,  BACKES BRADLEY J ,  JUDD ANDREW S ,  MULHERN MATHEW M ,  STEWART KENT D

IPC: C07C217/54 ,  C07C211/40 ,  C07D213/38 ,  C07D213/68 ,  C07D317/64

CPC classification number: C07C211/48 ,  C07C211/40 ,  C07C217/52 ,  C07C217/54 ,  C07C217/74 ,  C07C217/84 ,  C07C217/86 ,  C07C225/22 ,  C07C229/42 ,  C07C229/48 ,  C07C229/60 ,  C07C233/43 ,  C07C233/78 ,  C07C235/46 ,  C07C237/24 ,  C07C237/30 ,  C07C237/42 ,  C07C255/54 ,  C07C255/58 ,  C07C311/22 ,  C07C311/36 ,  C07C317/22 ,  C07C317/36 ,  C07C2601/14 ,  C07C2601/16 ,  C07D207/16 ,  C07D209/08 ,  C07D209/48 ,  C07D211/46 ,  C07D211/60 ,  C07D211/62 ,  C07D213/30 ,  C07D213/38 ,  C07D213/64 ,  C07D213/68 ,  C07D213/74 ,  C07D213/82 ,  C07D217/04 ,  C07D263/56 ,  C07D263/60 ,  C07D277/04 ,  C07D277/64 ,  C07D295/135 ,  C07D295/185 ,  C07D295/205 ,  C07D317/66 ,  C07D319/18 ,  C07D333/34 ,  C07D333/38 ,  C07D409/04 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04

Abstract: The present invention relates to compounds, which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, metabolic syndrome , hyperinsulinemia, obesity, atherosclerosis, various immunomodulatory diseases, and other diseases.

Abstract translation: 本发明涉及抑制二肽基肽酶IV（DPP-IV）的化合物，其可用于预防或治疗糖尿病，特别是II型糖尿病，以及高血糖症，代谢综合征，高胰岛素血症，肥胖症，动脉粥样硬化，各种免疫调节疾病 ，等疾病。

公开(公告)号：WO2004026822A3

公开(公告)日：2004-05-06

申请号：PCT/US0329018

申请日：2003-09-15

Applicant: ABBOTT LAB

Inventor： MADAR DAVID ,  PEI ZHONGHUA ,  PIREH DAISY ,  DJURIC STEVAN W ,  WIEDEMAN PAUL E ,  YONG HONG ,  FEENSTRA MELISSA J ,  KOPECKA HANA ,  LI XIAOFENG ,  LONGENECKER KENTON ,  SHAM HING L ,  STEWART KENT D ,  SZCZEPANKIEWICZ BRUCE G

IPC: A61P37/02 ,  C07D207/16 ,  C07D207/26 ,  C07D207/27 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D417/12 ,  A61K31/401 ,  A61K31/4439 ,  A61K31/506

CPC classification number: C07D207/27 ,  C07D207/16 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D417/12

Abstract: The present invention relates to compounds of formula I which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases. Or pharmaceutically acceptable salts or prodrugs thereof, wherein X,R,R ,R and R have the definitions given in the description.

Abstract translation: 本发明涉及抑制二肽基肽酶IV（DPP-IV）的式I化合物，其可用于预防或治疗糖尿病，特别是II型糖尿病，以及高血糖症，X综合征，高胰岛素血症，肥胖症，动脉粥样硬化和 各种免疫调节疾病。 或其药学上可接受的盐或前药，其中X，R，R 1，R 2和R 3具有说明书中给出的定义。

公开(公告)号：BRPI0615102A2

公开(公告)日：2011-05-03

申请号：BRPI0615102

申请日：2006-08-25

Applicant: ABBOTT LAB

Inventor： PEI ZHONGHUA ,  GELDERN THOMAS VON ,  MADAR DAVID J ,  LI XIAOFENG ,  BASHA FATIMA ,  YONG HONG ,  LONGENECKER KENTON L ,  BACKES BRADLEY J ,  JUDD ANDREW S ,  MULHERN MATHEW M ,  STEWART KENT D

IPC: C07C211/40 ,  A61K31/137 ,  C07C211/54 ,  C07C211/62 ,  C07D213/38 ,  C07D213/68 ,  C07D317/64 ,  C07D487/04

Abstract: The present invention relates to compounds, which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II, as well as hyperglycemia, metabolic syndrome, hyperinsulinemia, obesity, atherosclerosis, various immunomodulatory diseases, and other diseases.

公开(公告)号：MX2010005530A

公开(公告)日：2010-06-02

申请号：MX2010005530

申请日：2008-11-20

Applicant: ABBOTT LAB

Inventor： BARNES DAVID M ,  WU-WONG JINSHYUN RUTH ,  LI XIAOFENG ,  HENGEVELD JOHN E ,  GELDERN THOMAS W VON ,  BURKALOW JUFANG H ,  HAIGHT ANGHONY R ,  MCLAUGHLIN MAUREEN A ,  NOONAN WILLIAM T ,  PEI ZHONGHUA

IPC: C07C401/00

Abstract: La presente invención se refiere a compuestos que son activadores del receptor de vitamina D, composiciones que comprenden dichos compuestos, métodos para usar dichos compuestos y composiciones, procesos para preparar dichos compuestos e intermediarios obtenidos durante dichos procesos.

公开(公告)号：DK1560811T3

公开(公告)日：2007-12-10

申请号：DK03774478

申请日：2003-09-15

Applicant: ABBOTT LAB

Inventor： MADAR DAVID ,  PEI ZHONGHUA ,  PIREH DAISY ,  DJURIC STEVAN W ,  WIEDEMAN PAUL E ,  YONG HONG ,  MICHMERHUIZEN MELISSA J ,  KOPECKA HANA ,  LI XIAOFENG ,  LONGENECKER KENTON ,  SHAM HING L ,  STEWART KENT D ,  SZCZEPANKIEWICZ BRUCE G

IPC: C07D207/00 ,  A61P37/02 ,  C07D207/16 ,  C07D207/26 ,  C07D207/27 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D417/12

Abstract: The present invention relates to compounds of formula I which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases. Or pharmaceutically acceptable salts or prodrugs thereof, wherein X,R,R ,R and R have the definitions given in the description.

公开(公告)号：PT1560811E

公开(公告)日：2007-11-14

申请号：PT03774478

申请日：2003-09-15

Applicant: ABBOTT LAB

Inventor： STEWART KENT D ,  SHAM HING L ,  MADAR DAVID ,  PEI ZHONGHUA ,  PIREH DAISY ,  DJURIC STEVAN W ,  WIEDEMAN PAUL E ,  YONG HONG ,  MICHMERHUIZEN MELISSA J ,  KOPECKA HANA ,  LI XIAOFENG ,  LONGENECKER KENTON ,  SZCZEPANKIEWICZ BRUCE G

IPC: C07D207/00 ,  A61P37/02 ,  C07D207/16 ,  C07D207/26 ,  C07D207/27 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D417/12

公开(公告)号：AT368647T

公开(公告)日：2007-08-15

申请号：AT03774478

申请日：2003-09-15

Applicant: ABBOTT LAB

Inventor： MADAR DAVID ,  PEI ZHONGHUA ,  PIREH DAISY ,  DJURIC STEVAN ,  WIEDEMAN PAUL ,  YONG HONG ,  MICHMERHUIZEN MELISSA ,  KOPECKA HANA ,  LI XIAOFENG ,  LONGENECKER KENTON ,  SHAM HING ,  STEWART KENT ,  SZCZEPANKIEWICZ BRUCE

IPC: C07D207/00 ,  A61P37/02 ,  C07D207/16 ,  C07D207/26 ,  C07D207/27 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D417/12

Abstract: The present invention relates to compounds of formula I which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases. Or pharmaceutically acceptable salts or prodrugs thereof, wherein X,R,R ,R and R have the definitions given in the description.

公开(公告)号：AU2003282800A1

公开(公告)日：2004-04-08

申请号：AU2003282800

申请日：2003-09-15

Applicant: ABBOTT LAB

Inventor： SZCZEPANKIEWICZ BRUCE G ,  MADAR DAVID ,  PEI ZHONGHUA ,  PIREH DAISY ,  DJURIC STEVAN W ,  WIEDEMAN PAUL E ,  YONG HONG ,  FEENSTRA MELISSA J ,  KOPECKA HANA ,  LI XIAOFENG ,  LONGENECKER KENTON ,  SHAM HING L ,  STEWART KENT D

IPC: A61P37/02 ,  C07D207/16 ,  C07D207/26 ,  C07D207/27 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D417/12 ,  C07D207/00

Abstract: The present invention relates to compounds of formula I which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases. Or pharmaceutically acceptable salts or prodrugs thereof, wherein X,R,R ,R and R have the definitions given in the description.

公开(公告)号：NZ591609A

公开(公告)日：2012-10-26

申请号：NZ59160906

申请日：2006-08-25

Applicant: ABBOTT LAB

Inventor： PEI ZHONGHAU ,  VON GELDERN THOMAS ,  MADAR DAVID J ,  LI XIAOFENG ,  BASHA FATIMA ,  YONG HONG ,  LONGENECKER KENTON L ,  BACKES

IPC: C07D317/64 ,  A61K31/135 ,  A61K31/137 ,  C07C211/40 ,  C07C211/54 ,  C07C211/62 ,  C07D213/38 ,  C07D213/68 ,  C07D487/04

Abstract: Disclosed are trans-6-(phenyl)cyclohex-3-en-1-amine / trans-2-(phenyl)cyclohex-4-enyl-amine derivatives as represented by the general formula (I), wherein the substituents are as disclosed herein. Representative compounds include trans-6-(2-chlorophenyl)cyclohex-3-en-1-amine, trans-6-(2,4-dichlorophenyl)cyclohex-3-enyl-amine, 4-{ [trans-5-amino-4-(2,4-dichlorophenyl)-2-pyridin-3-ylcyclohex-1 -en-1-yl]methoxy} benzonitrile, trans-methyl 3-{ { 5-amino-4-(2,4-dichlorophenyl)-2-pyridin-3-ylcyclohex-1-en-1-yl]methoxy} benzoate, trans-3-(phenoxymethyl)-6-(2,4,5-trifluorophenyl)cyclohex-3-en-1-amine, trans-3-{ [4-(methylsulfonyI)phenoxy] methyl} -6-(2,4,5-trifluorophenyl)cyclohex-3-en-1-amine, N-(3-{ [trans-5-amino-4-(2,4,5-trifluorophenyl)cyclohex-1-en-1-yl)methoxy } phenyl)acetamide, 3-{ [trans-5-amino-4-(2,4,5-trifluorophenyl)cyclohex-1-en-1-yl]methoxy} -4-fluorobenzoic acid, trans-3-{ [3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]methyl} -6-(2,4,5-trifluorophenyl)cyclohex-3-en-1-amine and trans-3-[(4-acetylpiperazin-1-yI)methyl]-6-(2,4,5-trifluorophenyl)cyclohex -3-en-1-amine. Further disclosed is a pharmaceutical composition which comprises a therapeutically effective amount of a compound as defined above, in combination with a pharmaceutically suitable carrier for the treatment of diseases selected from the group consisting of cardiovascular disease, atherosclerosis, cerebrovascular diseases, diseases and disorders of the central nervous system, schizophrenia, anxiety, bipolar disease, depression, insomnia, cognitive disorders, gastrointestinal diseases and disorders, cancer, inflammation and inflammatory diseases, respiratory diseases and disorders, musculo-skeletal disorders, osteoporosis, menopausal symptoms, periodontal diseases, gingivitis, and various immunomodulatory diseases.